Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159731 · ClinicalTrials.gov registry record · Phase 4
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00159731 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 160 participants.
The verdict
NCT00159731, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)
Interventions
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159731
The ClinicalTrials.gov registry entry for NCT00159731 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pregabalin is the first listed.
NCT00159731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00159731 about?
NCT00159731 is a clinical study titled "Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy". The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)
What is the current status of trial NCT00159731?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2005-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00159731?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00159731?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.